Dopamine in Parkinson's disease
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Dopamine neuron systems in the brain: An update
Björklund, A., & Dunnett, S. B. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.006 · Cited by 1,777
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
(2008) · Cited by 889
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14748 · Cited by 702
Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.
Levey, A. I., Hersch, S. M., Rye, D. B., Sunahara, R. K., Niznik, H. B., Kitt, C. A., Price, D. L., Maggio, R., Brann, M. R., & Ciliax, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.8861 · Cited by 626
Dopamine receptors –IUPHAR R eview 13
Beaulieu, J., Espinoza, S., & Gainetdinov, R. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12906 · Cited by 521
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
Rashid, A. J., So, C. H., Kong, M. M. C., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., & George, S. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604049104 · Cited by 492
Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone
Wang, S., Che, T., Levit, A., Shoichet, B. K., Wacker, D., & Roth, B. L. (2018) · Nature · doi:10.1038/nature25758 · Cited by 483
The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress
Juárez Olguín, H., Calderón Guzmán, D., Hernández García, E., & Barragán Mejía, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9730467 · Cited by 462
Cell-Type-Specific Control of Brainstem Locomotor Circuits by Basal Ganglia
Roseberry, T. K., Lee, A. M., Lalive, A. L., Wilbrecht, L., Bonci, A., & Kreitzer, A. C. (2016) · Cell · doi:10.1016/j.cell.2015.12.037 · Cited by 395
60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis
Grattan, D. R. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0213 · Cited by 348
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine
Bisaglia, M., Mammi, S., & Bubacco, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610893200 · Cited by 303
Mishra, A., Singh, S., & Shukla, S. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518779829 · Cited by 276
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Interventions to Address the Academic Impairment of Children and Adolescents with ADHD
Raggi, V. L., & Chronis, A. M. (2006) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-006-0006-0 · Cited by 272
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases
Djajadikerta, A., Keshri, S., Pavel, M., Prestil, R., Ryan, L., & Rubinsztein, D. C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.035 · Cited by 236
Effects of pH and Oxidants on the First Steps of Polydopamine Formation: A Thermodynamic Approach
Salomäki, M., Marttila, L., Kivelä, H., Ouvinen, T., & Lukkari, J. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b02304 · Cited by 236
Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes
Stahl, S. M. (2017) · CNS Spectrums · doi:10.1017/s1092852917000608 · Cited by 232
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Martel, J. C., & Gatti McArthur, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01003 · Cited by 229
Dopamine Oxidation and Autophagy
Muñoz, P., Huenchuguala, S., Paris, I., & Segura-Aguilar, J. (2012) · Parkinson's Disease · doi:10.1155/2012/920953 · Cited by 214
Molecular Neuropharmacology: A Foundation for Clinical Neuroscience
Bloom, F. E. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1339-c · Cited by 206
Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons
Guillot, T. S., & Miller, G. W. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8059-y · Cited by 201
Dopamine in Health and Disease: Much More Than a Neurotransmitter
Franco, R., Reyes-Resina, I., & Navarro, G. (2021) · Biomedicines · doi:10.3390/biomedicines9020109 · Cited by 199
Dunevall, J., Fathali, H., Najafinobar, N., Lovric, J., Wigström, J., Cans, A.-S., & Ewing, A. G. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512972f · Cited by 196
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Siafis, S., Tzachanis, D., Samara, M., & Papazisis, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170630163616 · Cited by 185
Dopamine Autoxidation Is Controlled by Acidic pH
Umek, N., Geršak, B., Vintar, N., Šoštarič, M., & Mavri, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00467 · Cited by 169
Ayano, G. (2016) · Journal of Mental Disorders and Treatment · doi:10.4172/2471-271x.1000120 · Cited by 163
The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus
Niznik, H. B., Fogel, E. F., Fassos, F. F., & Seeman, P. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02580.x · Cited by 154
Van Laar, V. S., Mishizen, A. J., Cascio, M., & Hastings, T. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.03.004 · Cited by 152
Pharmacology of signaling induced by dopamine D1-like receptor activation
Undieh, A. S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.003 · Cited by 147
Tan, S. H., Karri, V., Tay, N. W. R., Chang, K. H., Ah, H. Y., Ng, P. Q., Ho, H. S., Keh, H. W., & Candasamy, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.101 · Cited by 146
Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration
Zhang, S., Wang, R., & Wang, G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00454 · Cited by 142
Marsden, C. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706473 · Cited by 140
Cartier, E. A., Parra, L. A., Baust, T. B., Quiroz, M., Salazar, G., Faundez, V., Egaña, L., & Torres, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054510 · Cited by 139
G protein-coupled receptor kinases as regulators of dopamine receptor functions
Gurevich, E. V., Gainetdinov, R. R., & Gurevich, V. V. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.010 · Cited by 138
New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy
Urs, N. M., Peterson, S. M., & Caron, M. G. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.10.011 · Cited by 137
Herrera, A., Muñoz, P., Steinbusch, H. W. M., & Segura-Aguilar, J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00034 · Cited by 135
Schmitt, K. C., Rothman, R. B., & Reith, M. E. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191056 · Cited by 132
Nano Secondary Ion Mass Spectrometry Imaging of Dopamine Distribution Across Nanometer Vesicles
Lovrić, J., Dunevall, J., Larsson, A. C., Ren, L., Andersson, S., Meibom, A., Malmberg, P., Kurczy, M. E., & Ewing, A. G. (2016) · ACS Nano · doi:10.1021/acsnano.6b07233 · Cited by 109
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease
Finberg, J. P. M. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1952-7 · Cited by 106
Neuroprotection and dopamine agonists
Schapira, A. H. V. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s9 · Cited by 103
Han, X., Jing, M.-Y., Zhao, T.-Y., Wu, N., Song, R., & Li, J. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0023-3 · Cited by 103
D5 Dopamine Receptors are Required for Dopaminergic Activation of Phospholipase C
Sahu, A., Tyeryar, K. R., Vongtau, H. O., Sibley, D. R., & Undieh, A. S. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.053017 · Cited by 101
De Miranda, B. R., Rocha, E. M., Bai, Q., El Ayadi, A., Hinkle, D., Burton, E. A., & Timothy Greenamyre, J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.04.008 · Cited by 95
Paris, I. B., Perez-Pastene, C., Cárdenas, S., Iturra, P., Muñoz, P., Couve, E., Caviedes, P. A., & Segura‐Aguilar, J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9148-4 · Cited by 93
Bisaglia, M., Soriano, M. E., Arduini, I., Mammi, S., & Bubacco, L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.006 · Cited by 93
Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function
Belkacemi, L., & Darmani, N. A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105124 · Cited by 87
Indirect Pathway of Caudal Basal Ganglia for Rejection of Valueless Visual Objects
Kim, H. F., Amita, H., & Hikosaka, O. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.033 · Cited by 86
Modulation of Ion Channels in the Axon: Mechanisms and Function
Burke, K. J., & Bender, K. J. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00221 · Cited by 86
Prenatal Amino Acid Supplementation to Improve Fetal Growth: A Systematic Review and Meta-Analysis
Terstappen, F., Tol, A. J. C., Gremmels, H., Wever, K. E., Paauw, N. D., Joles, J. A., van der Beek, E. M., & Lely, A. T. (2020) · Nutrients · doi:10.3390/nu12092535 · Cited by 86
Local and global consequences of reward-evoked striatal dopamine release
Li, N., & Jasanoff, A. (2020) · Nature · doi:10.1038/s41586-020-2158-3 · Cited by 82
Neurotoxin Mechanisms and Processes Relevant to Parkinson’s Disease: An Update
Segura‐Aguilar, J., & Kostrzewa, R. M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9519-y · Cited by 81
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 76
Loss of Homeostasis in the Direct Pathway in a Mouse Model of Asymptomatic Parkinson's Disease
Escande, M. V., Taravini, I. R. E., Zold, C. L., Belforte, J. E., & Murer, M. G. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0492-15.2016 · Cited by 71
Paulus, W., & Schomburg, E. D. (2006) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2006.01.004 · Cited by 69
TIDAL WAVES: Network mechanisms in the neuroendocrine control of prolactin release
Lyons, D. J., & Broberger, C. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.001 · Cited by 68
Biosa, A., Arduini, I., Soriano, M. E., Giorgio, V., Bernardi, P., Bisaglia, M., & Bubacco, L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00276 · Cited by 68
Slaney, T. R., Mabrouk, O. S., Porter‐Stransky, K. A., Aragona, B. J., & Kennedy, R. T. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300158p · Cited by 66
Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease
Struzyna, L. A., Browne, K. D., Brodnik, Z. D., Burrell, J. C., Harris, J. P., Chen, H.-C. I., Wolf, J. A., Panzer, K. V., Lim, J. T., Duda, J. E., et al. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2698 · Cited by 66
Huenchuguala, S., Muñoz, P., Zavala, P., Villa, M., Cuevas, C., Ahumada, U., Graumann, R., Nore, B. F., Couve, E., Mannervik, B., et al. (2014) · Autophagy · doi:10.4161/auto.27720 · Cited by 65
Botticelli, L., Bonaventura, E. M. D., Bello, F. D., Giorgioni, G., Piergentili, A., Romano, A., Quaglia, W., Cifani, C., & Bonaventura, M. V. M. D. (2020) · Nutrients · doi:10.3390/nu12082288 · Cited by 65
Genetic causes of Parkinson?s disease: UCHL-1
Healy, D. G., Abou‐Sleiman, P. M., & Wood, N. W. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0917-3 · Cited by 57
Domperidone and Parkinson’s Disease
Parkes, J. D. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_20 · Cited by 57
Systems Level Neuroplasticity in Drug Addiction
Feltenstein, M. W., & See, R. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011916 · Cited by 55
Sun, Y., Pham, A. N., Hare, D. J., & Waite, T. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00859 · Cited by 50
Domperidone and Parkinsonʼs Disease
Parkes, J. D. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198612000-00003 · Cited by 50
Stable Expression of Short Interfering RNA for DT-Diaphorase Induces Neurotoxicity
Lozano, J., Muñoz, P., Nore, B. F., LeDoux, S., & Segura-Aguilar, J. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100182a · Cited by 49
Registered nurses' involvement in advance care planning: an integrative review
Rietze, L., & Stajduhar, K. (2015) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2015.21.10.495 · Cited by 47
Neurotoxicity of metal mixtures
Andrade, V., dos Santos, A. P. M., & Aschner, M. (2021) · Advances in neurotoxicology · doi:10.1016/bs.ant.2020.12.003 · Cited by 47
Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway
Raghunathan, R., Polinski, N. K., Klein, J., Hogan, J., Chun, S., Khatri, K., Leon, D. R., McComb, M. E., Manfredsson, F. P., Sortwell, C. E., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000680 · Cited by 44
Dopamine Release Dynamics in the Tuberoinfundibular Dopamine System
Stagkourakis, S., Dunevall, J., Taleat, Z., Ewing, A. G., & Broberger, C. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2339-18.2019 · Cited by 42
A Complete Assessment of Dopamine Receptor- Ligand Interactions through Computational Methods
Bueschbell, B., Barreto, C. A. V., Preto, A. J., Schiedel, A. C., & Moreira, I. S. (2019) · Molecules · doi:10.3390/molecules24071196 · Cited by 41
Historical Overview: Introduction to the Dopamine Receptors
Seeman, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-333-6_1 · Cited by 39
Pezzella, A., Crescenzi, O., Natangelo, A., Panzella, L., Napolitano, A., Navaratnam, S., Edge, R., Land, E. J., Barone, V., & d'Ischia, M. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo0615807 · Cited by 39
Yohn, S. E., Galbraith, J., Calipari, E. S., & Conn, P. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00601 · Cited by 36
D. Mousseau, D., & B. Baker, G. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805219969 · Cited by 36
Badillo‐Ramírez, I., Saniger, J. M., & Rivas-Arancibia, S. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104514 · Cited by 36
The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain
Tolleson, C., & Claassen, D. O. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800792794 · Cited by 34
Pharmacology of Dopamine and Its Receptors
Kaur, S., Singh, S., Jaiswal, G., Kumar, S., Hourani, W., Gorain, B., & Kumar, P. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_5 · Cited by 31
Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease
de Natale, E. R., Niccolini, F., Wilson, H., & Politis, M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.08.003 · Cited by 30
Heteromerization of dopaminergic receptors in the brain: Pharmacological implications
Misganaw, D. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105600 · Cited by 30
From metabolic connectivity to molecular connectivity: application to dopaminergic pathways
Verger, A., Horowitz, T., Chawki, M. B., Eusébio, A., Bordonné, M., Azulay, J., Girard, N. J., & Guedj, É. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04574-3 · Cited by 25
Jefri, M., Bell, S., Peng, H., Hettige, N. C., Maussion, G., Soubannier, V., Wu, H., Silveira, H., Théroux, J., Moquin, L., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0180 · Cited by 24
Dopamine in psychiatry: a historical perspective
Foley, P. B. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01987-0 · Cited by 22
Dopamine D1 and D4 receptors contribute to light adaptation in ON-sustained retinal ganglion cells
Flood, M. D., & Eggers, E. D. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00218.2021 · Cited by 18
Joffe, M. E., & Conn, P. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0192-8 · Cited by 17
Effect of perinatal asphyxia and carbamazepine treatment on cortical dopamine and DOPAC levels
López‐Pérez, S. J., Morales‐Villagrán, A., & Medina‐Ceja, L. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0117-3 · Cited by 16
Mondin, G., Haft, M., Wisser, F. M., Leifert, A., Mohamed‐Noriega, N., Dörfler, S., Hampel, S., Grothe, J., & Kaskel, S. (2014) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2014.08.027 · Cited by 15
Ivanova, S. А., Alifirova, V. M., Pozhidaev, I. V., Freidin, M. B., Zhukova, I. A., Paderina, D. Z., Жукова, Н. Г., Mironova, Y. A., Владимирович, Т. В., Fedorenko, O. Y., et al. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29903 · Cited by 15
Enhancement in dopamine reduces generous behaviour in women
Artigas, S. O., Liu, L., Strang, S., Burrasch, C., Hermsteiner, A., Münte, T. F., & Park, S. Q. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226893 · Cited by 15
Molinaro, G., Battaglia, G., Riozzi, B., Storto, M., Fucile, S., Eusebi, F., Nicoletti, F., & Bruno, V. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.10.009 · Cited by 14
Raza, M. F., & SU, S. (2020) · Applied Ecology and Environmental Research · doi:10.15666/aeer/1801_13171327 · Cited by 14
Dopamine: a modulator of circadian rhythms/biological clock
Kant, R., Meena, M. K., & Pathania, M. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20210285 · Cited by 10
The role of dopamine D1 receptors in MDMA-induced memory impairments
Squire, H., Youn, J., Ellenbroek, B. A., & Harper, D. N. (2020) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2020.107322 · Cited by 8
Dopamine Synthesis as a Mechanism of Brain Plasticity in Nigrostriatal System Pathology
Kolacheva, A. A., & Ugrumov, M. V. (2018) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672918020096 · Cited by 5
Dopamine Receptors and Dopamine Release
KESSLER, R. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00012-9 · Cited by 3
Une voie dopaminergique descendante pour contrôler le mouvement
Fougère, M., & Ryczko, D. (2018) · médecine/sciences · doi:10.1051/medsci/20183405005 · Cited by 2
Cited by
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Xu, X., Iqbal, Z., Xu, L., Wen, C., Duan, L., Xia, J., Yang, N., Zhang, Y., & Liang, Y. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13610 · Cited by 68
Metadata
- Authors
- Latif, S., Jahangeer, M., Maknoon Razia, D., Ashiq, M., Ghaffar, A., Akram, M., El Allam, A., Bouyahya, A., Garipova, L., Ali Shariati, M., Thiruvengadam, M., & Azam Ansari, M.
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 522
- Pages
- 114-126
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W3188628968
- Cited by
- 340
- References
- 106
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.